Press releases

Pharmaleads to present at BioTrinity 2018 in London

Paris, France, [19 April 2018] – Pharmaleads, an emerging pharmaceutical company developing innovative non-opiate products for the management of acute and chronic severe pain, will present at BioTrinity 2018 in London on Tuesday, April 24th at 3.35pm. Michel Wurm, VP Medical Affairs, will introduce Pharmaleads and its innovative compounds, PL265 and PL37, which protect enkephalins, […] Read full post »

Pharmaleads to Present at Biotech Showcase 2018 in San Francisco

Paris, France, 3rd January 2018 – Pharmaleads, an emerging pharmaceutical company developing innovative non-opiate and non-addictive products for the management of acute and chronic severe pain, today announces its participation at the upcoming 10th Annual Biotech Showcase™ Conference to be held in San Francisco (CA, United States) on January 8 – 10, 2018. Thierry Bourbié, […] Read full post »

Meeting of Pharmaleads Clinical Advisory Board Confirms Clinical Development Plans for PL265 and PL37

Pharmaleads Clinical Advisory Board met on November 21 2017 in Paris to discuss the future clinical development of its two Dual ENKephalinase inhibitors (DENKIs). The CAB comprises world-renowned pain specialists; Professor Nadine Attal and Dr. Didier Bouhassira from Ambroise Paré Hospital in Paris, Professor Andrew Rice from Imperial College in London and Dr. Dinesh Selvarajah […] Read full post »

Older posts

Page 1 of 212
Discover our publications
NEWS RELEASES